PIONEERING VASCULAR ACCESS HEALTH
Cardiovascular disease (CVD) and Chronic Kidney Disease (CKD) remains the single greatest cause of death worldwide. CKD patients have an increased risk of developing CVD which is a major cause of death in this population (17.9 million pA) and has become $100 Bn healthcare problem.
The only cure for CKD is organ transplant, therefore the majority patients progress to requiring thrice weekly haemodialysis sessions. In the USA this End-Stage-Renal-Dialysis population are ~1% of Medicare beneficiaries patients but consume 7% of the entire 1 Trillion Medicare budget. Vascular access is a lifeline for dialysis patients which connects their blood vessel to the machine that cleans their blood when their kidneys fail. Yet 50% of lines block in Year 1 with high complications rates and associated costs. VascuX has developed a platform technology with a focus on Arteriovenous Grafts (AVGrafts).
VascuX is addressing this urgent and critical challenge faced by patients with End-Stage-Renal-Disease (ESRD) due to Chronic Kidney Disease (CKD) – developing the next generation of self-reporting cardiovascular implants. This is a new modality of treatment via a unique sensor system, integrated into vascular grafts. The product not only diagnoses, but treats and predicts graft failure, redefining the paradigm of CKD patient care.
Texas has highest density of CKD-ESRD patients (17,809) in the World with 739 Dialysis centres. The team has identified 89.2% of this cohort are insured and 69% are over 65 years. As a strategic starting point for its pilot programs, VascuX will focus predominantly on the female patient population over 65, who are the largest users of arteriovenous grafts.
THE TEAM
Experts in cardiovascular and chronic kidney disease from the College of Medical, Veterinary and Life Sciences are leading this innovation. The diverse expertise of the VascuX team is its cornerstone, with vascular biologists, clinicians, bioengineers, and bioelectronic engineers. The team is evolving the regulatory roadmap and submission to the FDA is in progress. The team is also supported with a commercial champion and an IP manager to support the product development plan. The team have a published Full Health Economic Assessment (FHEA).
MEDTECH INNOVATION FUND SUPPORT
The MedTech Innovation fund has supported the advancement of the VascuX technology, enabling the production of a human-grade version of the device. Funding has also facilitated the completion of the Budget Impact Model and the groundwork for regulatory approvals steps, helping to de-risk the proposition.
VascuX aims to transform the lives of CKD patients, offering a cost-effective solution that resonates with clinicians and alleviates patient anxiety. The VascuX project is a testament to the power of collaboration and innovation in meeting a pressing global healthcare challenge.
FINAL OVERVIEW
VascuX aims to transform the lives of CKD patients, offering a cost-effective solution that resonates with clinicians and alleviates patient anxiety. The VascuX project is a testament to the power of collaboration and innovation in meeting a pressing global healthcare challenge.
More information: vascux.com